GR38032F, a 5HT3receptor antagonist, in
β
Michel Marty; Jean P. Droz; Pierre Pouillart; Bernard Paule; Nils Brion; Jacques
π
Article
π
1989
π
Springer
π
English
β 330 KB
A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/ m 2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as